Apimeds Pharmaceuticals Us Inc APUS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and Lōkahi Therapeutics to Advance Apitox Program
-
Apimeds Pharmaceuticals Investor News: Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
-
Rosen Law Firm Encourages Apimeds Pharmaceuticals US, Inc. Investors to Inquire About Securities Class Action Investigation – APUS
-
Apimeds Pharmaceuticals US Inc. Announces Material Breach of Merger Agreement by Inscobee Inc. (KS:006490) and Apimeds Inc.; Prepares Filing Emergency Action in Delaware Court of Chancery
Trading Information
- Previous Close Price
- $1.34
- Day Range
- $1.17–1.41
- 52-Week Range
- $0.95–5.97
- Bid/Ask
- $1.13 / $1.22
- Shares Outstanding
- 15.09M
- Market Cap
- $17.66M
- Volume/Avg
- 79,666 / 224,324
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Apimeds Pharmaceuticals Us Inc is a development-stage biopharmaceutical company. The Company operates its biopharmaceutical business. Its primary focus is the clinical development of Apitox, a purified honeybee venom-based drug candidate being evaluated for the treatment of pain and inflammation associated with knee osteoarthritis. The Company operates in two segments: the biopharmaceutical segment, which is focused on the clinical development of Apitox through Lokahi, and the digital asset operations segment, which encompasses the holding, sale, and advancement of the MindWaveDAO blockchain and related digital assets through MindWave.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- —
- Total Number of Employees
- 7
- Website
- https://www.apimedsus.com
Valuation
|
Metric
|
APUS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APUS
|
|---|---|
Quick Ratio | 0.17 |
Current Ratio | 0.90 |
Interest Coverage | −35.91 |
Quick Ratio
APUS
Profitability
|
Metric
|
APUS
|
|---|---|
Return on Assets (Normalized) | −45.00% |
Return on Equity (Normalized) | −49.50% |
Return on Invested Capital (Normalized) | −44.89% |
Return on Assets
APUS
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Wkvlmlhw | Clytr | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Brvvbswg | Xlskcx | $40B | |||
| Haleon PLC ADR
HLN
| Gbjzjkzf | Hrxhh | $40B | |||
| Zoetis Inc Class A
ZTS
| Qgpyplcxhd | Vwhl | $33B | |||
| Viatris Inc
VTRS
| Fhpqwkskh | Zpwh | $19B | |||
| Elanco Animal Health Inc
ELAN
| Ypyvz | Nklm | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Smyxwgjvc | Nyyb | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Ytmjrpykj | Jgfc | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| Wmjfdpzw | Kkfjhg | $2B | |||
| Perrigo Co PLC
PRGO
| Czhfjmz | Bwqzt | $2B |
United States